Dr Neil Conlon was awarded a BSc (Double Hons.) in Biology and Chemistry from Maynooth University in 2013. Following this, he completed his PhD in Cancer Biology at Dublin City University (DCU) in 2018. His PhD examined the ways in which breast cancers can become resistant to HER2-targeted therapies. Neil conducted postdoctoral research in DCU funded by Puma Biotechnology and was then awarded an Irish Research Council Enterprise Partnership Scheme postdoctoral fellowship, co-funded by Cancer Clinical Research Trust.

Neil is now a research fellow and group lead of the Breast and Gynaecological Oncology Targeted Therapies research group in DCU. The group aims to find new treatment options for breast and gynaecological cancers, using a comprehensive pre-clinical approach to investigate potential new treatments. The group also examines how drugs that are approved for other diseases can be repurposed to treat poor prognosis cancers.